Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Poor Calibration in Waters Empower CSV: A Root Cause of Equipment Qualification Failures

A German pharmaceutical manufacturer engaged Zamann Pharma Support to strengthen compliance in Equipment Qualification (EQ), specifically around Waters Empower CSV documentation and lifecycle controls.

Initially, the expectation focused on improving URS structure, protocols, and validation lifecycle documentation. However, during the assessment, a far more critical issue emerged.

The calibration and preventive maintenance (PM) system showed severe compliance gaps. For instance, sensors were overdue, critical instruments had not been calibrated for years, and maintenance occurred only after failures.

Moreover, no risk-based justification supported calibration intervals, and out-of-tolerance (OOT) events were often ignored or left undocumented. Most critically, equipment remained in production use despite known calibration failures.

From a GMP standpoint, this situation represented a major compliance risk because calibration and maintenance directly define whether qualification remains valid.

Challenges Faced

A detailed GAP analysis in Quality Management Systems is essential for identifying process deficiencies effectively.
  • Regulatory Scrutiny Risk: The system was under FDA inspection readiness pressure, so any gap in calibration or validation documentation could lead to 483 observations or regulatory penalties.
  • High Volume of Validation Documentation: The environment included extensive documentation (URS, FS, VMP, IQ/OQ/PQ protocols, test scripts, traceability matrices, and change control records), making consistency checks complex.
  • Complex Regulatory Framework: GAMP and FDA expectations require strong understanding of risk-based validation and lifecycle control, so aligning all documents required expert-level evaluation.
  • Time Sensitivity: The GAP Assessment had to be completed within a strict internal timeline to meet upcoming regulatory submission deadlines.

Zamann Pharma Support’s Approach

  • Project Initialization: Zamann began with a structured kick-off meeting involving all relevant stakeholders. The team clarified objectives, timelines, and key compliance concerns. In parallel, the existing validation lifecycle documentation was mapped to define the scope of the GAP analysis.
  • Document Review Against Regulatory Standards: Each document was systematically reviewed against FDA regulations and GAMP guidelines. Key focus areas included URS, FS, VMP, IQ/OQ/PQ protocols, traceability matrices, and change control records.
  • Evaluation of Key Compliance Topics: Risk assessments were analyzed against GAMP risk-based principles. In addition, testing protocols were reviewed for 21 CFR Part 11 compliance, including audit trails and electronic signatures. Furthermore, change control and deviation management processes were assessed for completeness.
  • Structured GAP Classification & CAPA Strategy: GAPs were classified as Critical, Major, and Minor based on compliance risk. CAPAs addressed each gap through URS/FS revision, protocol updates, and traceability improvements. Training and template optimization improved documentation quality and audit readiness.
  • CAPA Development:CAPAs were defined for each GAP based on risk and user needs. Actions included URS/FS revision, test protocol updates, and traceability matrix strengthening. Training programs and template optimization supported audit readiness.
  • Implementation Support: Zamann provided templates, conducted workshops, and established a CAPA tracking system to ensure controlled execution.

Results Achieved

  • Regulatory Compliance Alignment: The GAP Assessment and CAPA execution aligned the Waters Empower CSV documentation with FDA and GAMP5 expectations.
  • Improved Documentation Quality: Documentation became more structured, consistent, and significantly easier to manage during inspections.
  • Reduced Compliance Risk: Critical GAPs were identified and addressed, reducing the probability of regulatory findings or enforcement actions.
  • Stronger Team Capability: Through workshops and guided CAPA execution, the client team improved their understanding of validation lifecycle requirements.
  • On-Time Delivery: All assessment and remediation activities were completed within the required timeline, supporting internal regulatory readiness goals.
Laboratory
GMP qualification and lifecycle validation activities including IQ, OQ, and PQ supporting inspection readiness in pharmaceutical manufacturing.
Services

Qualification and Validation for GMP Systems

Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

FAQ

1. What happens to batch release decisions when equipment is used after a documented “calibration failed” status?

When equipment is used after a documented calibration failure, batch release becomes scientifically indefensible under GMP. Regulators treat this as a direct loss of control over critical process parameters, meaning all data generated during that period is potentially invalid. As a result, QA cannot justify release without a full retrospective impact assessment, and in many cases, entire batch sets are classified as non-releasable due to compromised measurement integrity.

2. Why do inspectors escalate repeated use of overdue or failed instruments to a system-level validation breakdown?

Because repeated use of non-calibrated or failed instruments demonstrates that lifecycle controls are not functioning in practice. Inspectors interpret this as evidence that the validated state is not being maintained, even if initial IQ/OQ/PQ was completed. This shifts the finding from a simple deviation to a systemic failure in equipment qualification governance, often triggering data integrity classification and extended inspection scope.

3. How does ignoring OOT calibration results silently invalidate equipment qualification over time?

When OOT results are not properly investigated, equipment drift remains undetected while being continuously used in production. Over time, this creates a hidden deviation from validated operating conditions. Regulators consider this a breakdown of lifecycle validation because the qualification assumption stable and controlled performance is no longer true. Consequently, the equipment is treated as unqualified retrospectively, and impacted historical data may be challenged.